Next Article in Journal
Modulation of NMDA Receptor Activity in Fibromyalgia
Next Article in Special Issue
Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Deimmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins
Previous Article in Journal
HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation
Previous Article in Special Issue
Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation
Review

Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies

1
Institut für Laboratoriumsmedizin, Klinische Chemie und Pathobiochemie, Charité—Universitätsmedizin Berlin, Campus Virchow-Klinikum, 13353 Berlin, Germany
2
Institut für Pharmazie, Freie Universität Berlin, 14195 Berlin, Germany
3
Institut für Lebensmittelchemie, TU Braunschweig, 38106 Braunschweig, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Stefan Barth
Received: 10 February 2017 / Revised: 21 March 2017 / Accepted: 24 March 2017 / Published: 29 March 2017
(This article belongs to the Special Issue Targeted Human Cytolytic Fusion Proteins)
Protein-based targeted toxins play an increasingly important role in targeted tumor therapies. In spite of their high intrinsic toxicity, their efficacy in animal models is low. A major reason for this is the limited entry of the toxin into the cytosol of the target cell, which is required to mediate the fatal effect. Target receptor bound and internalized toxins are mostly either recycled back to the cell surface or lysosomally degraded. This might explain why no antibody-targeted protein toxin has been approved for tumor therapeutic applications by the authorities to date although more than 500 targeted toxins have been developed within the last decades. To overcome the problem of insufficient endosomal escape, a number of strategies that make use of diverse chemicals, cell-penetrating or fusogenic peptides, and light-induced techniques were designed to weaken the membrane integrity of endosomes. This review focuses on glycosylated triterpenoids as endosomal escape enhancers and throws light on their structure, the mechanism of action, and on their efficacy in cell culture and animal models. Obstacles, challenges, opportunities, and future prospects are discussed. View Full-Text
Keywords: saponins; endosomal escape; efficacy enhancers; targeted toxins; immunotoxins; cytosolic drug delivery; controlled drug release; cancer treatment; endocytosis saponins; endosomal escape; efficacy enhancers; targeted toxins; immunotoxins; cytosolic drug delivery; controlled drug release; cancer treatment; endocytosis
Show Figures

Graphical abstract

MDPI and ACS Style

Fuchs, H.; Niesler, N.; Trautner, A.; Sama, S.; Jerz, G.; Panjideh, H.; Weng, A. Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies. Biomedicines 2017, 5, 14. https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines5020014

AMA Style

Fuchs H, Niesler N, Trautner A, Sama S, Jerz G, Panjideh H, Weng A. Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies. Biomedicines. 2017; 5(2):14. https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines5020014

Chicago/Turabian Style

Fuchs, Hendrik, Nicole Niesler, Alexandra Trautner, Simko Sama, Gerold Jerz, Hossein Panjideh, and Alexander Weng. 2017. "Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies" Biomedicines 5, no. 2: 14. https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines5020014

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop